Clinical trials: Mucormycosis
Mucorales Infection, Mucormycosis
Biomarkers for Invasive Mucormycosis
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization.
- Trial name
- BIM (NCT05406037)
- Testing
- Venous sample
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Mucormycosis; Pulmonary (Etiology)
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management of mucormycosis.
- Trial name
- NCT05468372
- Testing
- Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B
- Where
- India
- Volunteers
- 82 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Mucormycosis
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Background: Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole.
- Trial name
- AIM (NCT07191756)
- Testing
- Amphotericin B, Isavuconazole
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Qiu Ye
Aspergillosis Invasive, Mucormycosis
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric…
- Trial name
- NCT06440915
- Testing
- Theraputic drug monitoring, Isavuconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Children's Medical Center
Invasive Mucormycosis, Invasive Aspergillosis
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
- Trial name
- NCT03816176
- Testing
- Isavuconazonium sulfate
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pulmonary Mucormycosis
Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis
To assess the safety and feasibility of combined inhalational and intravenous amphotericin B therapy for the treatment of pulmonary mucormycosis.
- Trial name
- NCT04502381
- Testing
- Inhaled amp B deoxycholate+intravenous liposomal amp B, Intravenous liposomal amphotericin B alone
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Mucormycosis
COVID-19 and Rhino-orbital Mucormycosis
Detect the clinical presentation and outcome of post covid-19 fungal mucormycosis in patients referred to Minia university Hospital.
- Trial name
- NCT05212961
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Minia University
Mucormycosis
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
- Trial name
- NCT00419770
- Testing
- deferasirox, Liposomal amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Covid19, Mucormycosis
Mucormycosis in COVID-19
The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge.
- Conditions
- Covid19, Mucormycosis, Aspergillosis, Candida Infection
- Trial name
- MUNCO (NCT04935463)
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Montefiore Medical Center
COVID-19, Mucormycosis
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia.
- Trial name
- NCT05097664
- Where
- Iran
- Volunteers
- 250 people
- Sponsor
- Isfahan University of Medical Sciences
Mucormycosis
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19.
- Trial name
- NCT05074043
- Testing
- antiviral, surgical
- Where
- Egypt
- Volunteers
- 433 people
- Sponsor
- Assiut University
Mycoses
Descriptive Epidemiology on Management of Mucormycosis
This is an observational chart review of all patients with confirmed and probable diagnosis of mucormycosis at 19 centers across Indian hospital. Data will collect using a standardized CRF.
- Trial name
- NCT03429023
- Where
- 13 sites in India
- Volunteers
- 500 people
- Sponsor
- Fungal Infection Study Forum
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC